Latest news
25 items- PRThe RD Fund Announces Ocuphire Pharma's Acquisition of Opus GeneticsThe resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD) RALEIGH, N.C., Oct. 25, 2024 /PRNewswire/ -- The RD Fund (Retinal Degeneration Fund) – the venture arm of the Foundation Fighting Blindness – announces the all-stock acquisition of Opus Genetics, Inc. "Opus" (private) by Ocuphire Pharma, Inc., (NASDAQ:OCUP) a clinical-stage ophthalmic biopharmaceutical company. The companies have combined under the name of Opus Genetics to create a transformative biotech company committed to being a leader in the development of gene therapies for the treatment of inherited retinal diseases (IRDs). The combined company is trading on the Nasdaq under the ticker s
- INSIDERSEC Form 4 filed by Director Graves Adrienne L4 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERDirector Bennett Jean was granted 100,000 shares (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERSEC Form 3 filed by new insider Yerxa Benjamin R3 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERSEC Form 3 filed by new insider Graves Adrienne L3 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERSEC Form 3 filed by new insider Bennett Jean3 - Opus Genetics, Inc. (0001228627) (Issuer)
- SECOcuphire Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Completion of Acquisition or Disposition of Assets, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Ocuphire Pharma, Inc. (0001228627) (Filer)
- PROcuphire Pharma Announces Acquisition of Opus GeneticsAcquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations New OPGx-LCA5 Phase 1/2 6-month data demonstrate safety and visual improvement in early onset retinal degeneration Additional clinical data in LCA5 pediatric patients and BEST1 patients is expected in 2H 2025 LYNX-2 Phase 3 trial of Phentolamine Ophthalmic Solution 0.75% in patients with dim light disturbances remains on track for top-line data in Q1 2025 VEGA-3 Phase 3 trial of Phentolamine Ophthalmic Solution 0.75% in presbyopia remains on track for top-line data in H1 2025 Company will seek a strategic partner to continue development of
- PROcuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in OphthalmologyFARMINGTON HILLS, Mich., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced the publication of full results from two pivotal Phase 3 clinical trials (MIRA-2 and MIRA-3) that evaluated the safety and efficacy of RYZUMVI™ (Phentolamine Ophthalmic Solution 0.75%) for the treatment of pharmacologically-induced mydriasis in the peer-reviewed journal Ophthalmology. The results demonstrated that Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2
- PRUPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for PresbyopiaTop-line data from VEGA-3 Phase 3 trial expected in first half of 2025 Top-line data from LYNX-2 Phase 3 trial in patients with decreased visual acuity under low light conditions following keratorefractive surgery expected in first quarter of 2025 FARMINGTON HILLS, Mich., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that the VEGA-3 Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% for presbyopia has dosed its first participants. Pr
- PROcuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for PresbyopiaTop-line data from VEGA-3 Phase 3 trial expected in first half of 2025 Top-line data from LYNX-2 Phase 3 trial in patients with decreased visual acuity under low light conditions following keratorefractive surgery expected in first quarter of 2025 FARMINGTON HILLS, Mich., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that the VEGA-3 Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% for presbyopia has dosed its first participants. Pr
- SECSEC Form 10-Q filed by Ocuphire Pharma Inc.10-Q - Ocuphire Pharma, Inc. (0001228627) (Filer)
- SECOcuphire Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Ocuphire Pharma, Inc. (0001228627) (Filer)
- PROcuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate UpdateVEGA-3 Phase 3 Study of Phentolamine Ophthalmic Solution in Presbyopia is Recruiting Patients with Top-Line Data Expected in 2025 LYNX-2 Phase 3 Study of Phentolamine Ophthalmic Solution Continues Enrollment with Top-Line Data Expected in 2025 Preparatory Steps Towards Phase 2/3 with APX3330 in Diabetic Retinopathy are Ongoing Cash Position of $41.4 million Provides Runway Anticipated into mid-2025 FARMINGTON HILLS, Mich., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive e
- PROcuphire Pharma to Present at Two Investor Conferences in AugustFARMINGTON HILLS, Mich., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that George Magrath, M.D., M.B.A., M.S., Chief Executive Officer, will present at the Canaccord Genuity 44th Annual Growth Conference, to take place in Boston, MA, August 14, 2024, and at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, to take place virtually, on August 15, 2024. Event:Canaccord Genuity 44th Annual Growth ConferenceLocation:Boston, MAPresenter:Dr. George M
- NEWSOcuphire Pharma Participates In ARVO SIG Panel And ASRS 42nd Annual Scientific Meeting To Highlight APX3330 For Diabetic RetinopathyCEO to participate in ARVO SIG panel on oral medications for retinal diseasesZETA-1 Phase 2 clinical trial subset analysis to be presented during the ASRS 42nd Annual Scientific Meeting
- PROcuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in JulyCEO to participate in ARVO SIG panel on oral medications for retinal diseases ZETA-1 Phase 2 clinical trial subset analysis to be presented during the ASRS 42nd Annual Scientific Meeting FARMINGTON HILLS, Mich., July 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced it will participate in the Association for Research in Vision and Ophthalmology Special Interest Group (ARVO SIG) panel and the American Society of Retina Specialists (ASRS) 42nd Annual Scientific Meeti
- INSIDERDirector Rodgers Richard J was granted 41,143 shares, increasing direct ownership by 21% to 239,151 units (SEC Form 4)4 - Ocuphire Pharma, Inc. (0001228627) (Issuer)
- INSIDERDirector Pepose Jay was granted 41,143 shares, increasing direct ownership by 30% to 180,458 units (SEC Form 4)4 - Ocuphire Pharma, Inc. (0001228627) (Issuer)
- INSIDERDirector Manuso James S J was granted 41,143 shares, increasing direct ownership by 45% to 132,037 units (SEC Form 4)4 - Ocuphire Pharma, Inc. (0001228627) (Issuer)
- INSIDERDirector Gallagher Cam was granted 41,143 shares, increasing direct ownership by 115% to 77,047 units (SEC Form 4)4 - Ocuphire Pharma, Inc. (0001228627) (Issuer)
- INSIDERDirector Benton Susan was granted 41,143 shares, increasing direct ownership by 42% to 140,023 units (SEC Form 4)4 - Ocuphire Pharma, Inc. (0001228627) (Issuer)
- INSIDERDirector Ainsworth Sean was granted 41,143 shares, increasing direct ownership by 87% to 88,358 units (SEC Form 4)4 - Ocuphire Pharma, Inc. (0001228627) (Issuer)
- SECOcuphire Pharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Ocuphire Pharma, Inc. (0001228627) (Filer)
- NEWSOcuphire Pharma Announces Upcoming Presentations On Lead Candidate APX3330 For Diabetic Retinopathy At Clinical Trials At The Summit On June 8 And Retinal Imaging Biomarkers & Endpoints Summit June 25-27
OCUP FAQ
6 questionsWhat does Ocuphire Pharma Inc. do?
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances, and pharmacologically induced mydriasis, as well as that is in Phase II clinical trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal...Where does OCUP stock trade?
Ocuphire Pharma Inc. (OCUP) is listed on NASDAQ.What sector and industry is OCUP in?
Ocuphire Pharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about OCUP?
Ocuphire Pharma Inc. has had 1 recent analyst action on file. The most recent action was from HC Wainwright & Co.: Buy with a $2600.00 price target on 2021-11-24. Recent price targets cluster around $2600.00.What companies are similar to OCUP?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare OCUP side-by-side with any of them on Quantisnow.How can I track OCUP on Quantisnow?
Quantisnow aggregates Ocuphire Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OCUP to receive live email and push alerts on every new disclosure.